Putting its share price gains to good use, Clovis Oncology has acquired the Italian cancer drug developer Ethical Oncology Sciences (EOS) for an upfront consideration of US$200 M, including US$190 M in Clovis common stock and US$10 M in cash. The deal, which is potentially worth up to US$420 M, provides the company with rights in the US and Japan to lucitanib, a dual-selective inhibitor of fibroblast growth factor receptors 1 and 2 (FGFR1/2) and vascular endothelial growth factor receptors 1-3 (VEGFR1-3) that is commencing Phase II development for the treatment of breast and lung cancers.